Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 13, 1983 - Issue 6
25
Views
16
CrossRef citations to date
0
Altmetric
Research Article

The fate of dibenz[b,f]-1,4-oxazepine (CR) in the rat. Part II. Metabolism in vitro

, , &
Pages 361-372 | Received 13 Jan 1983, Published online: 22 Sep 2008
 

Abstract

1. CR (dibenz[b,f]-1,4-oxazepine) is metabolized by rat liver 105000 g supernatant fractions by (a) ring opening and reduction to 2-amino-2′-hydroxymethyldiphenyl ether and (b) oxidation at C11 to give a cyclic lactam.

2. Reaction (a) is NADPH-dependent, decreased by dialysis and methylene blue, whereas reaction (b) is heat-resistant, inactivated by dialysis, inhibited by CN. p-chloromercuribenzoate, amytal and menadione, and stimulated by methylene blue, phenazine methosulphate and 2,6-dichlorophenol indophenol. Reaction (a) is similar to that of aldehyde reductases (E.C.1.1.1.2) and reaction (b) to that of molybdenum hydroxylases (E.C.1.2.3.1).

3. Reaction (a) is also catalysed by an NADH-dependent enzyme in liver microsomes and subsequent hydroxylation of the lactam also occurs in this cell fraction.

4. Some extrahepatic metabolism of CR occurs via the same routes in kidney, small intestine and lung, though the yield is limited.

5. Digestive gland extract of Helix pomatia converts CR to its lactam in significant amounts.

6. The metabolism of CR in vitro is similar to that predicted from observations in vivo.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.